TrueTicker

NIFTY 500 › Chemicals

Chemicals · NIFTY 500

Clean Science and Technology Ltd.

CLEAN on NSE · 19 Nov 2026

NIFTY 500

696.95 ▼ -0.29 % on the day

Overview Technical Risk & rank Results Accounts Filings Guidance & governance

Filings

36 filings of CLEAN since January 2025.

presentation 9, transcript 8, board outcome 8, dividend 7, results 2, credit rating 2

FiledTypeSubject
05 Nov 2026transcript
Capex, Guidance, Results
Further to our letter dated 22nd October, 2026 and in terms of Regulation 30 read with Schedule III - Part A to the Listing Regulations, please find enclosed herewith the transcript of conference call on the Company s Q2 FY26-27 Earnings he
AI summary

Clean Science and Technology filed the transcript of its Q2 FY27 earnings conference call held on 31 October 2026.

Management said standalone Q2 revenue rose 11% sequentially to INR226 crore, with EBITDA margin of 36% and PAT margin of 24%; raw material cost rose to 41% of sales from 35% in Q1 FY27, and on a consolidated basis revenue was INR295 crore, with year-on-year growth of 23%.

Management said consolidated revenue for the year to date grew 17% to INR559 crore, with EBITDA of INR188 crore and PAT of INR129 crore.

Management said HALS revenue grew 2x year on year in the quarter, that input costs rose sharply due to Middle East conflict, and that the company could not pass on the price increase to Chinese-priced customers.

Management said Performance Chemical 2 is expected to commercialise in Q3 to Q4 FY27 and total investment in the subsidiary stands at INR900 crore.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Oct 2026presentation
Capex, Results
Clean Science And Technology Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation for Q2 and H1 FY2027 (quarter and half year ended 30 September 2026) filed by Clean Science and Technology Limited.

Consolidated Q2 FY2027 total revenue INR 299 crore (up 22% YoY from INR 245 crore); consolidated Q2 FY2027 PAT INR 56 crore (up 0.5% YoY) and EBITDA INR 92 crore with EBITDA margin 31.2%.

Consolidated H1 FY2027 total revenue INR 568 crore (up 16% YoY); H1 FY2027 PAT INR 129 crore (up 3% YoY); standalone H1 FY2027 PAT INR 129 crore (down 9% YoY).

Management stated that the new segment (Clean Fino Chem Ltd, CFCL) added about INR 48 crore of YoY sales and turned PAT positive, and that margins moderated due to geopolitical headwinds.

Management said about INR 150 crore of capex was incurred in H1 FY2027 for CFCL, that CFCL completed advanced HALS product trials with Geneus Chem AG, with commercial launch expected in H2 FY2026-27, and that Performance Chemical 2 is expected to be commercialised in H2 FY27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Oct 2026board outcome
Results
Further to our letter dated 17th October, 2026 and in compliance with Regulation 30 read with Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ( SEBI Listing Regul
AI summary

Clean Science and Technology Limited filed the outcome of its board meeting held on 31 October 2026, approving the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026.

The filing encloses the results along with a limited review report from the statutory auditors, Price Waterhouse Chartered Accountants LLP, which states nothing has come to their attention that the statement has not been prepared in accordance with Ind AS 34 and Regulation 33.

The standalone results statement is presented in million rupees, except per share data, with face value of Re 1 per share and paid-up equity capital of 106.28 million.

The board meeting commenced at 12 noon and concluded at 2.20 pm.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Sep 2026credit rating
Rating
Clean Science And Technology Limited has informed the Exchange about Credit Rating
AI summary

Clean Science and Technology Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, dated 24 September 2026.

CRISIL Ratings Limited reaffirmed the company's long-term rating at CRISIL AA-/Stable, as per its letter dated 23 September 2026.

CRISIL reaffirmed the company's short-term rating at CRISIL A1+.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2026transcript
Acquisition, Capex, Guidance, Results
Transcript of conference call on the Company s Q1 FY26-27 Earnings.
AI summary

Clean Science and Technology Limited filed the transcript of its Q1 FY27 earnings conference call held on 1 August 2026.

Management said consolidated sales reached about INR 264 crores, the highest ever, up 7% sequentially and 10% year on year; standalone revenue was INR 203 crores, with EBITDA of INR 87 crores and PAT of INR 73 crores.

Management said HALS is now 22% of sales, volumes were about 1,000 tons, and annualised HALS revenue is expected at INR 250-300 crores.

Management described a strategic collaboration with Swiss partner Geneus Chem, with an expected INR 300-350 crores of additional revenue over 3 to 4 years, and said Performance Chemical 2 will commercialise by Q3 FY27.

Management said year-on-year standalone sales fell 6% mainly due to supply-side headwinds, including a about two-week shutdown at a primary Indian supplier, while demand remains steady.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Aug 2026presentation
Acquisition, Capex, Results
Clean Science And Technology Limited has informed the Exchange about Investor Presentation
AI summary

Clean Science and Technology Limited filed its investor presentation for the quarter ended 30 June 2026 (Q1 FY2027) under Regulation 30 of the SEBI LODR Regulations.

Consolidated total revenue for Q1 FY2027 was Rs 268 crore, up 8% quarter-on-quarter from Rs 249 crore and up 11% year-on-year from Rs 243 crore; consolidated EBITDA was Rs 96 crore (EBITDA margin 36.5%) and consolidated PAT was Rs 73 crore (PAT margin 27.8%).

Standalone total revenue was Rs 207 crore, EBITDA Rs 87 crore (42.7%) and PAT Rs 73 crore (36.0%).

Management said the company reported steady performance despite global headwinds, that about Rs 100 crore of capex was incurred in Q1 FY2027 towards its wholly owned subsidiary Clean Fino Chem Ltd (CFCL), and that a wholly owned European subsidiary is being set up to expand its global footprint.

Management said Performance Chemical 2 is expected to be commercialised by Q3 FY27 and that the top four legacy products' share of sales has fallen from about 85% in Q4 FY23 to about 60%, with HALS at 22% of sales.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Aug 2026board outcome
Acquisition, Capex, Dividend / buy-back, Management change, Results
Board approved 1) Unaudited Standalone & Consolidated Financial Results Q1FY27 2) 23rd Annual General Meeting on Saturday, 12.08.2026 to be held VC/ OAVM 3) Cut-off Date for Final dividend payment is 05.09.2026 and dividend payment date is
AI summary

Board of Clean Science and Technology Limited, meeting held 1 August 2026, approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, with limited review report.

Board convened the 23rd AGM on 12 September 2026 via video conferencing/other audio-visual means and approved a final dividend payable on 30 September 2026 to members on record date 5 September 2026.

Board co-opted Mr. Krishnakumar Satyanarain Saboo (DIN: 11863005) as Additional Director until the 23rd AGM and recommended his appointment as Whole-time Director for five years from 1 August 2026 to 31 July 2031; he was also appointed Factory Occupier from 1 August 2026.

Board approved incorporation of a wholly owned foreign subsidiary in the Netherlands via Clean Fino-Chem Limited, with initial capital of EUR 50,000 at EUR 1 per share.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 May 2026transcript
Capex, Dividend / buy-back, Guidance, Results
Transcript of conference call on the Company s Q4 and financial year ended 31st March, 2026 Earnings
AI summary

Clean Science and Technology filed the transcript of its Q4 and FY26 earnings conference call held on 14 May 2026.

Standalone Q4 FY26 revenue rose 8% QoQ to INR 193 crore; standalone FY26 revenue declined 12% YoY to INR 796 crore (from INR 900 crore), per management.

Management said the Board declared a final dividend of INR 4 per equity share (400% of face value of INR 1).

Management said Clean Fino-Chem's Hydroquinone/Catechol plant is in initial stabilisation, with capex for Performance Chemical 2 expected to commercialise by September 2026.

Management described the macro environment as very tricky for FY27 and said it is hard to forecast FY27 given dependence on global macro factors.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 May 2026presentation
Capex, Dividend / buy-back, Results
Clean Science And Technology Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation for Q4 FY2026 and FY2026 filed by Clean Science and Technology Limited, with corrections of typographical errors to the earlier version.

Q4 FY2026 consolidated total revenue Rs. 249 crore (Q3 FY2026: Rs. 219 crore; Q4 FY2025: Rs. 264 crore); consolidated PAT Rs. 58 crore (Q4 FY2025: Rs. 74 crore).

FY2026 consolidated total revenue Rs. 957 crore (FY2025: Rs. 967 crore); consolidated PAT Rs. 230 crore (FY2025: Rs. 266 crore).

FY2026 standalone total revenue Rs. 815 crore (FY2025: Rs. 922 crore); standalone PAT Rs. 251 crore (FY2025: Rs. 292 crore).

Management stated total capex of about Rs. 220 crore in FY2026, primarily for investment in Clean Fino Chem Ltd. (wholly owned subsidiary), and that the Board approved a final dividend of Rs. 4 per share, implying a total payout ratio of 25% for the year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 May 2026presentation
Capex, Dividend / buy-back, Results
Clean Science And Technology Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation for Q4 FY2026 and FY2026 results of Clean Science and Technology Limited, filed 14 May 2026.

Q4 FY2026 consolidated revenue from operations was Rs 249 crore (Rs 264 crore in Q4 FY2025, down 6% YoY) and consolidated PAT was Rs 58 crore (Rs 74 crore in Q4 FY2025, down 22% YoY).

FY2026 consolidated total revenue was Rs 957 crore (Rs 967 crore in FY2025) and consolidated PAT was Rs 230 crore (Rs 266 crore in FY2025).

Management said EBITDA margins were resilient in challenging market conditions and that sales momentum continued at HALS, with a rebound in the base business visible.

Management said total capex of about Rs 220 crore was incurred in FY2026, mainly for investment in Clean Fino Chem Ltd, and the Board approved a final dividend of Rs 4 per share, implying a payout ratio of 25% for the year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 May 2026dividend
Capex, Dividend / buy-back, Results
Recommended final dividend of Rs. 4/- (400%) per Equity Share of the face value of Re. 1/- each for the Financial Year ended 31st March 2026. The Final Dividend is subject to the approval of the members at the ensuing Annual General Meeting
AI summary

Board of Clean Science and Technology Limited, at its meeting on 14 May 2026, approved audited standalone and consolidated financial results for the fourth quarter and financial year ended 31 March 2026.

The Board recommended a final dividend of Rs 4 per equity share (400%) on face value Re 1, subject to shareholder approval at the AGM; record date and payment date to be determined later.

The Board approved an additional investment of Rs 200 crore, in one or more tranches, in Clean Fino-Chem Limited, a wholly owned subsidiary.

The Board approved re-appointment of CNK JBMS & Associates as internal auditors and Dhananjay V. Joshi & Associates as cost auditors for FY 2026-27.

The statutory auditors, Price Waterhouse Chartered Accountants LLP, issued unmodified audit reports on the standalone and consolidated results.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 May 2026board outcome
Capex, Dividend / buy-back, Results
Outcome of Board Meeting held on 14th May, 2026 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
AI summary

Board of Clean Science and Technology Limited approved audited standalone and consolidated financial results for Q4 and financial year ended 31 March 2026 at its meeting on 14 May 2026.

Board recommended a final dividend of Rs. 4 per equity share (400%) on face value of Re. 1, subject to shareholder approval at the ensuing AGM; record date and payment date to be determined later.

Board approved additional investment of Rs. 200 crore in one or more tranches in wholly owned subsidiary Clean Fino-Chem Limited.

Board approved re-appointment of CNK JBMS & Associates as internal auditors and Dhananjay V. Joshi & Associates as cost auditors for FY 2026-27.

Statutory auditors Price Waterhouse Chartered Accountants LLP issued unmodified audit reports on the standalone and consolidated results.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Feb 2026transcript
Capex, Dividend / buy-back, Guidance, Management change, Results
Clean Science And Technology Limited has informed the Exchange about Transcript
AI summary

Clean Science and Technology filed the transcript of its Q3 FY26 earnings conference call held on 31 January 2026.

Management said standalone revenue moderated to INR180 crores quarter-on-quarter, with EBITDA of INR72 crores (40% margin) and PAT of INR52 crores (29% margin); consolidated revenue was INR216 crores, with EBITDA margin 33% and PAT margin 21%.

Management said HALS sales grew 55% year-on-year in the quarter, Clean Fino Chem Limited reached EBITDA breakeven, and the hydroquinone and catechol plant was commercialized in December 2025.

Management said Performance Chemical 1 revenue is now expected at about INR260 crores versus INR320-odd crores earlier, and Performance Chemical 2 is expected to commercialize in Q1 FY27.

The company approved an interim dividend of INR2 per share and appointed two new board members, Mr. Raj Kamal and Mrs. Pallavi Gokhale.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jan 2026presentation
Capex, Dividend / buy-back, Results
Clean Science And Technology Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation for Q3 FY2026 and 9M FY2026 (quarter and nine months ended 31 December 2025), filed under Regulation 30 of SEBI LODR.

Q3 FY26 standalone total revenue was Rs. 185 crore, down 20% year on year and 13% quarter on quarter; standalone EBITDA was Rs. 72 crore with a 40.3% margin; standalone PAT was Rs. 52 crore.

9M FY26 standalone total revenue was Rs. 618 crore, down 9% year on year; standalone PAT was Rs. 193 crore, down 10%.

Management said EBITDA margins were resilient in challenging market conditions, and that about Rs. 165 crore of capex was incurred in 9M FY26, mainly for Clean Fino Chem Ltd (wholly owned subsidiary); Hydroquinone and Catechol were commercialised in Q3 FY26 and Performance Chemical 2 construction is on track.

The Board approved an interim dividend of Rs. 2 per share.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jan 2026dividend
Dividend / buy-back, Results
Declared Interim Dividend of Rs. 2/- (200%) per Equity Share of FV of Re.1/- each for FY 2025-26.
AI summary

Clean Science and Technology Limited's board met on 31 January 2026 and approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025.

The board declared an interim dividend of Rs. 2 per equity share (200%) on a face value of Re. 1 each for FY 2025-26.

The record date for the interim dividend is 6 February 2026, and the dividend will be paid on 20 February 2026.

The filing encloses the limited review reports issued by Price Waterhouse Chartered Accountants LLP on both sets of results.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jan 2026board outcome
Dividend / buy-back, Results
Board approved at their meeting held on Saturday, 31-01-2026 a) Un-audited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended 31st December, 2025 b) Declared Interim Dividend of Rs. 2/- (200%) per Equity Sha
AI summary

Board of Clean Science and Technology Limited approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with limited review reports from Price Waterhouse Chartered Accountants LLP attached.

The Board declared an interim dividend of Rs. 2 per equity share (200%) on a face value of Re. 1 each for FY 2025-26.

Record date for the interim dividend is 6 February 2026, and payment is scheduled for 20 February 2026 (as printed in the filing).

The board meeting was held on 31 January 2026 and was filed under Regulation 30 of the SEBI Listing Regulations, 2015.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Nov 2025transcript
Capex, Results
Transcript of conference call on the Company s Q2 FY25-26 Earnings.
AI summary

Clean Science and Technology Limited filed the transcript of its Q2 FY26 earnings conference call held on 6 November 2025.

Management (Siddharth Sikchi, Executive Director and Promoter) said standalone revenue fell 5% sequentially and 8% year-on-year to INR206 crores, mainly due to lower sales of established products; standalone EBITDA was about INR90 crores and standalone PAT about INR65 crores.

Management said consolidated revenue was steady at INR240 crores, with consolidated EBITDA of INR87 crores and PAT of INR55 crores; HALS monthly volumes averaged about 260 tons, up over 25% quarter on quarter.

Management said Performance Chemical 1 is in chemical trials, with commercialisation targeted this month and sampling to customers targeted for December, and that about INR150 crores was invested in subsidiary CFCL during the first half.

The transcript excerpt ends during a question on FY26 outlook; no guidance figure is given in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2025presentation
Capex, Guidance, Results
Clean Science And Technology Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation for Q2 FY2026 and H1 FY2026 results (quarter and half year ended 30 September 2025) filed by Clean Science and Technology Limited.

Q2 FY2026 standalone total revenue was INR 211 crore, down 7% year-on-year from INR 228 crore; standalone PAT was INR 65 crore (PAT margin 31.3%).

Q2 FY2026 consolidated total revenue was INR 245 crore, up 3% year-on-year; consolidated PAT was INR 55 crore versus INR 59 crore a year earlier.

H1 FY2026 standalone total revenue was INR 431 crore (down 3%) and standalone PAT was INR 141 crore (up 1%); consolidated H1 revenue was INR 488 crore (up 6%) and consolidated PAT was INR 125 crore (flat).

Management stated that favourable product mix led to resilient EBITDA margins, that operating leverage benefits are expected as newly launched products scale, that chemical trials for performance chemical 1 are underway, and that construction for performance chemical 2 is on track.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2025board outcome
Legal, Management change, Results
Further to our letter dated 14th October, 2025 and in compliance with Regulation 30 read with Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ( SEBI Listing Regul
AI summary

Board meeting outcome dated 5 November 2025 (meeting held 6 November 2025) approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025.

The Board recommended to shareholders, by postal ballot, continuation of Ms. Madhu Dubhashi as Non-executive Independent Director after she attains age 75 on 6 February 2026, up to her term expiry on 19 February 2026.

The Board recommended re-appointment of Mr. Keval Navinchandra Doshi as Non-executive Independent Director for a second term of 5 years from 6 February 2026 to 5 February 2031.

The Board recommended appointment of Mr. Raj Kamal and Ms. Pallavi Gokhale as Non-executive Independent Directors for 5 years from 6 November 2025 to 5 November 2030.

The Board recommended change in designation of Mr. Ashok Ramnarayan Boob to Whole Time Director - Executive Vice Chairman, and of Mr. Siddhartha Ashok Sikchi to Managing Director from 1 April 2026 to 31 March 2031; postal ballot e-voting runs from 17 November 2025 to 16 December 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2025board outcome
Management change, Results
Further to our letter dated 14th October, 2025 and in compliance with Regulation 30 read with Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ( SEBI Listing Regul
AI summary

Board of Clean Science and Technology Limited approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025 (meeting held 6 November 2025).

The Board recommended to shareholders, by postal ballot, continuation of Ms. Madhu Dubhashi as Non-executive Independent Director from 6 February 2026 up to 19 February 2026, and re-appointment of Mr. Keval Navinchandra Doshi as Non-executive Independent Director for a second term of 5 years from 6 February 2026 to 5 February 2031.

The Board recommended appointment of Mr. Raj Kamal and Ms. Pallavi Gokhale as Non-executive Independent Directors for 5 years from 6 November 2025 to 5 November 2030.

The Board recommended change in designation of Mr. Ashok Ramnarayan Boob from Managing Director to Whole Time Director - Executive Vice Chairman, and of Mr. Siddhartha Ashok Sikchi from Whole Time Director to Managing Director effective 1 April 2026 up to 31 March 2031.

Postal ballot record date is 10 November 2025; e-voting runs from 17 November 2025 to 16 December 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Aug 2025credit rating
Rating
Clean Science And Technology Limited has informed the Exchange about Credit Rating
AI summary

Clean Science and Technology Limited intimated under Regulation 30 of SEBI LODR that CRISIL Ratings Limited assigned its credit ratings on 25 August 2025.

Long-term rating: CRISIL AA-/Stable (Reaffirmed).

Short-term rating: CRISIL A1+ (Reaffirmed).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Jul 2025transcript
Capex, Guidance, Results
Further to our letter dated 10th July, 2025 and in terms of Regulation 30 read with Schedule III - Part A to the Listing Regulations, please find enclosed herewith the transcript of conference call on the Company s Q1 FY25-26 Earnings held
AI summary

Clean Science and Technology Limited filed the transcript of its Q1 FY25-26 earnings conference call held on 17 July 2025.

Management (Siddharth Sikchi) said standalone revenue fell 9% sequentially to INR 217 crores, with EBITDA of INR 101 crores (record margin of over 46%) and PAT of INR 77 crores; consolidated sales were INR 240 crores and consolidated EBITDA INR 100 crores (42% margin).

Management said HALS sales were about INR 24 crores in the quarter, with volume close to 580 tons, and that it is holding to its FY26 HALS target of INR 210 crores.

Management said Performance Chemicals 1 is expected to commercialise in Q2 FY26 with commercial production from September, and Performance Chemicals 2 by Q4 FY26; INR 80 crores was invested in subsidiary Clean Fino-Chem Limited during the quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Jul 2025presentation
Capex, Results
Clean Science And Technology Limited has informed the Exchange about Investor Presentation
AI summary

Clean Science and Technology filed its Q1 FY2026 (quarter ended 30 June 2025) investor presentation under Regulation 30 of the SEBI LODR Regulations.

Consolidated total revenue for Q1 FY2026 was INR 243 crore, up 8% year-on-year and down 8% quarter-on-quarter from INR 264 crore in Q4 FY2025.

Consolidated EBITDA for Q1 FY2026 was INR 100 crore (EBITDA margin 40.9%); standalone EBITDA was INR 101 crore (margin 46.4%), which the presentation describes as a record high margin since listing, led by favourable product mix.

Consolidated PAT for Q1 FY2026 was INR 70 crore, up 6% year-on-year; standalone PAT was INR 77 crore.

Management stated that water trials for Performance Chemical 1 are expected to commence in August and that capex for Performance Chemical 2 is on track.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Jul 2025board outcome
Dividend / buy-back, Results
Clean Science And Technology Limited has submitted to the Exchange, the financial results for the period ended June 30, 2025
AI summary

Board of Clean Science and Technology Limited approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with limited review report from statutory auditors (Price Waterhouse Chartered Accountants LLP).

Standalone revenue from operations for Q1 FY26 was Rs 2,199.06 million, profit for the period Rs 765.74 million, and basic EPS Rs 7.21 (not annualised), versus Rs 2,453.86 million revenue in the quarter ended March 31, 2025.

Board approved the 22nd AGM on September 11, 2025 through video conferencing.

Final dividend for FY 2024-25 to be paid on September 26, 2025, with record date September 4, 2025.

Register of members closed from September 5, 2025 to September 11, 2025 (both days inclusive) for AGM and final dividend.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Jul 2025dividend
Dividend / buy-back, Results
Further to our letter dated 8th July, 2025 and in compliance with Regulation 30 read with Schedule III and other applicable provisions of the SEBI Listing Regulations, 2015 we hereby inform you that, the Board of Directors of the Company, a
AI summary

Clean Science and Technology Limited's board approved the unaudited standalone and consolidated results for the quarter ended 30 June 2025 on 17 July 2025, with a limited review report from the statutory auditors.

Standalone revenue from operations for Q1 FY26 was Rs 2,199.06 million, against Rs 2,453.86 million in the quarter ended 31 March 2025 and Rs 2,173.14 million in the quarter ended 30 June 2024; standalone profit for the period was Rs 765.74 million.

The board fixed 4 September 2025 as the record date for the final dividend for FY 2024-25, to be paid on 26 September 2025.

The 22nd AGM will be held on 11 September 2025 through video conferencing or other audio-visual means; register of members will be closed from 5 to 11 September 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 May 2025transcript
Capex, Dividend / buy-back, Guidance, Results
Transcript of conference call on the Company s Q4 and financial year ended 31st March, 2025 Earnings.
AI summary

Clean Science and Technology Limited filed the transcript of its Q4 and FY'25 earnings conference call held on 22 May 2025.

Management said standalone Q4 revenue rose 4.5% sequentially to Rs 238 crores, with EBITDA of Rs 105 crores and PAT of Rs 79 crores (EBITDA margin 43.8%); consolidated Q4 sales were Rs 256 crores.

Management said HALS sales were about 2,000 tons in FY'25 (about 3x FY'24), with revenue of roughly Rs 80 crores, and targeted about 4,500 tons and around Rs 210 crores for FY'26, with full ramp-up by FY'28 at over 10,000 tons capacity.

Management said Rs 215 crores was invested in subsidiary Clean Fino-Chem in FY'25, new performance chemical products are expected to commercialise by Q3 FY'26 and Q4 FY'26, and the Board recommended a final dividend of Rs 4 per share.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2025presentation
Capex, Dividend / buy-back, Results
Clean Science And Technology Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation for Q4 and FY2025 results (quarter and year ended 31 March 2025) filed under Regulation 30 of SEBI LODR.

Standalone FY2025 total revenue Rs 922 crore (up 17% YoY from Rs 789 crore); EBITDA Rs 399 crore (EBITDA margin 43.4%); PAT Rs 292 crore (up 18% YoY).

Consolidated FY2025 total revenue Rs 967 crore (up 22% YoY); EBITDA Rs 388 crore; PAT Rs 264 crore (up 8% YoY).

Q4 FY2025 standalone total revenue Rs 245 crore (up 9% YoY); PAT Rs 79 crore.

Total capex of about Rs 225 crore during FY2025, mainly for Clean Fino Chem Ltd (wholly owned subsidiary); capex on track for Performance Chemical 1 and 2.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2025board outcome
Dividend / buy-back, Legal, Management change, Results
Clean Science And Technology Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
AI summary

Board meeting outcome filed on 22 May 2025 approving audited standalone and consolidated results for Q4 and FY ended 31 March 2025, with an unmodified audit opinion from Price Waterhouse Chartered Accountants LLP.

Board recommended a final dividend of Rs 4 per equity share (400%) on face value Re 1 for FY2024-25, subject to AGM approval; book closure and payment dates to be decided later.

Board approved re-appointment of Krishnakumar Ramnarayan Boob (DIN 00410672) and Siddhartha Ashok Sikchi (DIN 02351154) as Whole Time Directors for 5 years from 1 April 2026 to 31 March 2031, subject to shareholder approval at the AGM.

Board approved appointment of J B Bhave & Co., Company Secretaries, as Secretarial Auditors for five years from FY 2025-26 to FY 2029-30, subject to shareholder approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2025dividend
Dividend / buy-back, Management change, Results
Board approved: a) Audited Standalone & Consolidated Financial Results for FY25. b) Recommended final dividend of Rs.4/- (400%) per Share c) Re-appointment of Mr. Krishnakumar Boob as a Whole Time Director for a term of 5 years w.e.f. 01-04
AI summary

Board meeting held on 22 May 2025 approved audited standalone and consolidated financial results for Q4 and financial year ended 31 March 2025, with an unmodified audit opinion from Price Waterhouse Chartered Accountants LLP.

Board recommended a final dividend of Rs 4 (400%) per equity share of face value Re 1, subject to shareholder approval at the AGM; book closure and payment dates to be determined later.

Board approved re-appointment of Krishnakumar Ramnarayan Boob (DIN 00410672) and Siddhartha Ashok Sikchi (DIN 02351154) as Whole Time Directors for 5 years from 1 April 2026 to 31 March 2031, subject to shareholder approval at the AGM.

Board approved appointment of J B Bhave & Co., Company Secretaries, as Secretarial Auditors for 5 years from FY 2025-26 to FY 2029-30, subject to shareholder approval at the AGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Feb 2025transcript
Capex, Dividend / buy-back, Guidance, Results
Transcript of conference call on the Company s Q3 FY24-25 Earnings.
AI summary

Clean Science and Technology Limited filed the transcript of its Q3 FY25 earnings conference call held on 30 January 2025.

Management (Executive Director Siddharth Sikchi) said standalone EBITDA rose 8% sequentially to Rs. 102 crores with EBITDA margin of 45%; consolidated sales were Rs. 240 crores, consolidated EBITDA Rs. 98 crores (margin 41.5%) and consolidated profit Rs. 66 crores.

Management said HALS sales volume scaled to about 190 tons per month, with a December exit rate of 200 tons per month, and CAPEX of Rs. 160 crores was incurred in the first nine months of FY25, mainly at subsidiary Clean Fino-Chem.

Management said the Board approved an interim dividend of Rs. 2 per share and expects its performance segment's new product to commercialise by H2 FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2025results
Capex, Dividend / buy-back, Results
Integrated Financials for the Quarter ended 31.12.2024
AI summary

Board of Clean Science and Technology Limited approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024 on 30 January 2025.

Standalone Q3 FY25 revenue from operations was Rs 2,315.57 million and profit for the period was Rs 741.09 million, against Rs 1,947.31 million and Rs 624.15 million in the year-ago quarter.

Standalone nine-month revenue from operations was Rs 6,769.30 million and profit was Rs 2,136.94 million, against Rs 5,639.60 million and Rs 1,728.78 million a year earlier.

Board declared interim dividend of Rs 2 per equity share (200% on face value of Re 1), with record date 7 February 2025 and payment on 21 February 2025.

Board approved additional investment of Rs 300 crore in one or more tranches in wholly owned subsidiary Clean Fino-Chem Limited.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2025presentation
Capex, Dividend / buy-back, Results
Clean Science And Technology Limited has informed the Exchange about Investor Presentation
AI summary

Clean Science and Technology Limited filed its Q3 FY2025 and 9M FY2025 investor presentation (quarter and nine months ended 31 December 2024) under Regulation 30 of SEBI LODR.

Standalone Q3 FY2025 total revenue was Rs 231.6 crore (up 19% y-o-y) and PAT was Rs 74.1 crore (up 19% y-o-y); standalone 9M FY2025 total revenue was Rs 676.9 crore (up 20% y-o-y) and PAT was Rs 213.7 crore (up 24% y-o-y).

Consolidated Q3 FY2025 total revenue was Rs 240.8 crore and PAT was Rs 65.6 crore; consolidated 9M FY2025 total revenue was Rs 703.0 crore and PAT was Rs 190.4 crore.

Capex of about Rs 160 crore was incurred during 9M FY2025, primarily towards Clean Fino Chem Ltd., a wholly owned subsidiary; DHDT and BHT were commercialised in Q3 FY2025.

The Board approved an interim dividend of Rs 2 per share.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2025dividend
Capex, Dividend / buy-back, Results
Board approved a) Un-audited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended 31.12.2024.b) Declared Interim Dividend of Rs. 2/- (200%) per Equity Share of F.V. of Re.1/- each for FY25. c) approved additio
AI summary

Board of Clean Science and Technology Limited approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024.

Standalone revenue from operations for the quarter was Rs 2,315.57 million and profit for the period was Rs 741.09 million, against Rs 1,947.31 million and Rs 624.15 million in the same quarter of the previous year.

Board declared interim dividend of Rs 2 per equity share (200%) on face value of Re 1 for FY 2024-25, with record date 7 February 2025 and payment on 21 February 2025.

Board approved additional investment of Rs 300 crores in one or more tranches in wholly owned subsidiary Clean Fino-Chem Limited.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2025results
Capex, Dividend / buy-back, Results
Clean Science And Technology Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Clean Science and Technology Limited's board on 30 January 2025 approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024.

Standalone revenue from operations for Q3 FY25 was Rs 2,315.57 million and profit for the period was Rs 741.09 million, versus Rs 1,947.31 million revenue and Rs 624.15 million profit a year earlier; nine-month standalone revenue was Rs 6,769.30 million and profit Rs 2,136.94 million.

The board declared an interim dividend of Rs 2 per equity share (200% on face value of Re 1), with record date 7 February 2025 and payment on 21 February 2025.

The board approved additional investment of Rs 300 crores in one or more tranches in Clean Fino-Chem Limited, a wholly owned subsidiary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2025dividend
Capex, Dividend / buy-back, Results
Board approved a) Un-audited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended 31.12.2024.b) Declared Interim Dividend of Rs. 2/- (200%) per Equity Share of F.V. of Re.1/- each for FY25. c) approved additio
AI summary

Clean Science and Technology Limited filed the outcome of its board meeting held on 30 January 2025, including approval of unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2024.

Standalone nine-month revenue from operations was Rs 6,769.30 million and profit for the period was Rs 2,136.94 million; Q3 FY25 standalone revenue from operations was Rs 2,315.57 million and profit was Rs 741.09 million (figures in million as printed).

The board declared an interim dividend of Rs 2 per equity share (200% on face value of Re 1) for FY 2024-25, with record date 7 February 2025 and payment on 21 February 2025.

The board approved additional investment of Rs 300 crore in one or more tranches in Clean Fino-Chem Limited, a wholly owned subsidiary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2025dividend
Capex, Dividend / buy-back, Results
Board approved a) Un-audited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended 31.12.2024.b) Declared Interim Dividend of Rs. 2/- (200%) per Equity Share of F.V. of Re.1/- each for FY25. c) approved additio
AI summary

Board of Clean Science and Technology Limited approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024.

Standalone revenue from operations was Rs 2,315.57 million for the quarter and Rs 6,769.30 million for the nine months; standalone profit for the quarter was Rs 741.09 million (basic EPS Rs 6.97).

Board declared interim dividend of Rs 2 per equity share (200%) of face value Re 1 for FY 2024-25, with record date 7 February 2025 and payment on 21 February 2025.

Board approved additional investment of Rs 300 crores in one or more tranches in wholly owned subsidiary Clean Fino-Chem Limited.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in